MLICM
FATE icon

Metropolitan Life Insurance Company (MetLife)’s Fate Therapeutics FATE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,590
Closed -$33.7K – 736
2024
Q1 		$33.7K Buy
4,590
+2,446
+114% +$15.1K ﹤0.01% 1598
2023
Q4 		$8.02K Sell
2,144
-2,381
-53% -$5.62K ﹤0.01% 2242
2023
Q3 		$9.59K Hold
4,525
– – ﹤0.01% 2229
2023
Q2 		$21.5K Hold
4,525
– – ﹤0.01% 1892
2023
Q1 		$25.8K Sell
4,525
-447
-9% -$2.7K ﹤0.01% 1749
2022
Q4 		$50.2K Hold
4,972
– – ﹤0.01% 1469
2022
Q3 		$111K Hold
4,972
– – 0.01% 950
2022
Q2 		$123K Hold
4,972
– – 0.01% 941
2022
Q1 		$193K Sell
4,972
-16,007
-76% -$620K 0.01% 837
2021
Q4 		$1.23M Sell
20,979
-865
-4% -$49K 0.02% 836
2021
Q3 		$1.29M Buy
21,844
+238
+1% +$18.7K 0.02% 785
2021
Q2 		$1.88M Buy
21,606
+1,363
+7% +$110K 0.03% 558
2021
Q1 		$1.67M Buy
20,243
+298
+1% +$28.6K 0.02% 613
2020
Q4 		$1.81M Sell
19,945
-828
-4% -$51.4K 0.03% 526
2020
Q3 		$830K Buy
20,773
+1,657
+9% +$57.9K 0.01% 852
2020
Q2 		$656K Buy
19,116
+686
+4% +$20.4K 0.01% 1022
2020
Q1 		$409K Sell
18,430
-1,170
-6% -$29.6K 0.01% 1172
2019
Q4 		$384K Hold
19,600
– – 0.01% 1492
2019
Q3 		$304K Sell
19,600
-823
-4% -$15.8K 0.01% 1604
2019
Q2 		$415K Hold
20,423
– – 0.01% 1425
2019
Q1 		$359K Hold
20,423
– – 0.01% 1509
2018
Q4 		$262K Buy
20,423
+3,956
+24% +$55.2K 0.01% 1631
2018
Q3 		$268K Hold
16,467
– – ﹤0.01% 1806
2018
Q2 		$187K Buy
16,467
+668
+4% +$7.36K ﹤0.01% 1986
2018
Q1 		$154K Buy
+15,799
New +$151K ﹤0.01% 2054

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FATE Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 4,590 shares — an estimated $33.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FATE in Q1 2018 and held it in 25 quarters. The position peaked at $1.88M in Q2 2021. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,590 Fate Therapeutics shares in Q2 2024, an estimated $33.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Fate Therapeutics in Q1 2018 and held it in 25 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Fate Therapeutics position peaked at $1.88M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.